Stocks That Fell to 3-Year Lows in the Week of Sept. 27

Live

Stocks get clobbered as Trump's China trade war intensifies. See the latest.

GuruFocus.com

Sun, Sep 29, 2019, 7:15 PM

Gilead Sciences is an American international pharmaceutical and biotechnology company that develops and commercializes therapeutics. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C and influenza. Some of the products the company developed include AmBisome, Atripla, Cayston, Emtriva and Flolan.

The company has a market cap of $79.66 billion; its shares were traded around $62.90 with a price-earnings ratio of 13.64 and a price-sales ratio of 3.63. The trailing 12-month dividend yield is 3.91%. The forward dividend yield is 3.98%. Gilead Sciences had an annual average earnings growth of 26.10% over the past 10 years.

On Sept. 9, Gilead Sciences announced the launch of the RADIAN initiative with the Elton John AIDS Foundation at the Fast-Track Cities 2019 conferences in London. RADIAN seeks to address new HIV infections and deaths from AIDS-related illnesses in Eastern Europe and Central Asia. The initiative consists of two elements, the Model Cities program and the Unmet Need fund.

Altria declined to $40.13

The price of Altria shares declined to $40.13 on Sept. 27, which is only 2.1% above the three-year low of $39.30.

Altria is one of the world's largest producers and marketers of cigarettes and other tobacco products.

The company has a market cap of $74.97 billion; its shares were traded around $40.13 with a price-earnings ratio of 11.94 and a price-sales ratio of 2.97. The trailing 12-month dividend yield is 8.07%. The forward dividend yield is 8.26%. Altria had an annual average earnings growth of 10.20% over the past 10 years.

On Aug. 27, Altria announced it is in discussions with Philip Morris International Inc. (PM) regarding a potential all-stock merger of equals. However, there is no assurance that any agreement or transaction will result from these discussions. Furthermore, there can also be no assurance that if an agreement is reached, that a transaction will be completed.

Regeneron Pharmaceuticals declined to $273.46

The price of Regeneron Pharmaceuticals shares declined to $273.46 on Sept. 27, which is only 0.8% above the three-year low of $271.37.

Regeneron Pharmaceuticals is an American biotechnology company. Originally, the company focused on neurotrophic factors and their regenerative capabilities, but has since branched out into the research of cytokine and tyrosine kinase receptors. The company is a component of both the Nasdaq 100 and the S&P 500.

The company has a market cap of $30.03 billion; its shares were traded around $273.46 with a price-earnings ratio of 15.20 and a price-sales ratio of 4.38. Regeneron Pharmaceuticals had an annual average earnings growth of 29.40% over the past five years.

On Aug. 28, Regeneron Pharmaceuticals announced that the U.S. District Court for the District of Delaware ruled in the company's favor and found that Amgen's (AMGN) asserted patient claims for antibodies targeting PCSK9 are invalid based on lack of enablement. The ruling overturned portions of an earlier jury verdict upholding the validity of three claims.

Carnival declined to $41.96

The price of Carnival shares declined to $41.96 on Sept. 27, which is only 1.7% above the three-year low of $41.23.

Carnival is a British-American cruise operator and currently the world's largest travel leisure company. IT has a combined fleet of over 100 vessels across 10 cruise line brands. The company is composed of two businesses, Carnival Corp. and Carnival PLC, which function as one entity. Carnival is the only company in the world to be listed on both the S&P 500 and FTSE 100 indexes.

Carnival has a market cap of $29.91 billion; its shares were traded around $41.96 with a price-earnings ratio of 10.08 and a price-sales ratio of 1.49. The trailing 12-month dividend yield is 4.76%. The forward dividend yield is 4.72%. Carnival had an annual average earnings growth of 6.80% over the past 10 years.

On Sept. 25, Carnival announced it has signed an agreement with the government of The Bahamas to build two major port developments. Under the agreement, it will develop a new cruise port destination for the Carnival Cruise Line on Grand Bahama, and the construction of a new addition on the Bahamian island of Little San Salvador.

Disclosure: I do not own stock in any of the companies mentioned in the article.

Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

This article first appeared on GuruFocus.